Production of a novel humanised anti Dendritic Cell Therapeutic Antibody for Graft Versus Host Disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/434523

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.

Funded Activity Details

Start Date: 01-01-2007

End Date: 01-01-2007

Funding Scheme: NHMRC Development Grants

Funding Amount: $202,500.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Allogeneic haematopoietic stem cell transplantation | Dendritic cell targeting therapeutic | Graft versus host disease | Haematopoietic stem cell transplantation | Leukaemia | Therapeutic antibody engineering and development

Related Links